Cellular Therapy Research
In addition to her interest in the preclinical development of cancer immunotherapy approaches for hematological and solid tumors, Dr. Savoldo provide support in writing protocols, developing standard operating procedures and training T-cell processing staff operating in the facility in order to implement T-cell therapy clinical trials at the University of North Carolina, Chapel Hill. Dr. Savoldo is also the assistant director of the Lineberger Immunotherapy Program.
Open Clinical Trials
|Diagnosis||Age Range||Study Title|
|ALL, Immune System Diseases, Immunoproliferative Disorders||1 Year and Older||Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch in Patient with Acute Lymphoblastic Leukemia|
|Lymphomas||3 years and Older||Phase I Study of Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of of Relapse of CD30+ Lymphomas after High Dose Therapy and Autologous Stem Transplantation (ATLAS)|